Reaction
Increased Viscosity Of Upper Respiratory Secretion reporting signals
As of the last recalculation, Increased Viscosity Of Upper Respiratory Secretion appears in 744 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is DORNASE ALFA (PRR 33.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dornase Alfa | 23 | 33.8 | 33.9 |
| Heparin Sodium | 15 | 31.1 | 31.2 |
| Mometasone Furoate | 34 | 23.9 | 23.9 |
| Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin | 17 | 23.6 | 23.7 |
| Naproxen Sodium, Pseudoephedrine Hydrochloride | 17 | 23.6 | 23.6 |
| Umeclidinium | 7 | 22.1 | 22.1 |
| Hydroxyurea | 16 | 21.6 | 21.6 |
| Guaifenesin | 21 | 19.8 | 19.8 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 7 | 15.8 | 15.9 |
| Amikacin | 9 | 14.9 | 14.9 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 5 | 13.5 | 13.5 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 18 | 12.4 | 12.4 |
| Eptinezumab-Jjmr | 4 | 12.4 | 12.4 |
| Daratumumab | 14 | 10.0 | 10.0 |
| Lifitegrast | 4 | 6.9 | 6.9 |
| Vigabatrin | 3 | 5.8 | 5.8 |
| Palivizumab | 3 | 5.5 | 5.5 |
| Dupilumab | 73 | 4.6 | 4.6 |
| Pimavanserin Tartrate | 8 | 4.1 | 4.1 |